Efforts to better predict tumor behavior and improve BC treatment led to the classification of BC by molecular subtypes, which include luminal ER+ (luminal A and luminal B), human epidermal growth factor receptor 2 (HER2)-enriched, and basal-like [22,23]. This evidence concerns the gene ESR1 and neoplasm.